<DOC>
	<DOCNO>NCT00424463</DOCNO>
	<brief_summary>This long-term , double-blind , placebo-controlled study MCI-186 treat ALS . This study long-term extension Study NCT00330681 ; Study NCT00330681 Phase 3 , randomize , double-blind , placebo control , parallel assignment , 24-week study treatment ALS . The objective study assess efficacy safety long-term intermittent therapy 60 mg MCI-186 ALS patient .</brief_summary>
	<brief_title>Expanded Controlled Study Safety Efficacy MCI-186 Patients With Amyotrophic Lateral Sclerosis ( ALS )</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Motor Neuron Disease</mesh_term>
	<mesh_term>Amyotrophic Lateral Sclerosis</mesh_term>
	<mesh_term>Phenylmethylpyrazolone</mesh_term>
	<mesh_term>Antipyrine</mesh_term>
	<criteria>Patients ware complete drug administration without discontinuation precede confirmatory study NCT00330681 . Patients complication Parkinson 's disease , schizophrenia , dementia , renal failure , severe complication , patient anamnesis hypersensitivity edaravone . Patients whose creatinine clearance 50mL/min less time completion drug administration study NCT00330681 . Pregnant , lactating , probably pregnant patient , patient want become pregnant , patient agree contraception . Patients participate clinical trial except study NCT00330681 . In addition exclusion criterion , patient judge inadequate participate study physician .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2013</verification_date>
	<keyword>Amyotrophic lateral sclerosis ( ALS )</keyword>
</DOC>